Extended Data Fig. 5: ST2 expression by ILC2s, mast cells, eosinophils, and neutrophils is largely unaffected by the type 1 Il1rl1 promoter deletion.

a, RNA-seq coverage tracks and detected splice junctions at the Il1rl1 locus of ILC2s¹⁰⁴ and mast cells¹⁰⁵. chr1:40,377,000-40,465,500; GRCm38.p6/mm10 is shown. b, Gating strategy for the analysis of Lin⁻CD45⁺ CD3⁻ CD127⁺ ILCs. c, Representative histograms showing ST2 expression by KLRG1⁺ IL-18R^- ILC2s isolated from lungs of WT or Il1rl1-ExAB^-/- mice (n = 4). d, Frequencies of ST2⁺ ILC2s and ST2 expression intensities (MFI). e, Gating strategy for the analysis of c-kit⁺ FcεRIa⁺ peritoneal mast cells. f, Representative histograms showing ST2 expression by peritoneal mast cells isolated from WT or Il1rl1-ExAB^-/- mice. g, Frequencies of ST2⁺ mast cells and ST2 expression intensities (MFI) (n = 4). h, Gating strategy for the analysis of bone marrow eosinophils and neutrophils. i, Representative FACS plots showing ST2 expression by eosinophils from WT, Il1rl1^-/- and Il1rl1-ExAB^-/- mice. j, Frequencies of ST2⁺ eosinophils and ST2 expression intensity of ST2⁺ eosinophils. k, Representative FACS plots showing ST2 expression by neutrophils from WT, Il1rl1^-/- and Il1rl1-ExAB^-/- mice. l, Frequencies of ST2⁺ neutrophils and ST2 expression intensity of ST2⁺ neutrophils (WT: n = 5, Il1rl1^-/-: n = 4, Il1rl1-ExAB^-/-: n = 4). Results are presented as mean ± SD with each dot representing one mouse. Data are representative of two experiments. P was determined using two-tailed t-tests (d,g,j,l) or one-way ANOVA with Tukey’s post hoc test (j,l, left panels).

Source data